Evidence map›Paper›PMID 32161909›Full record

ArticleJournal of translational autoimmunity2019

Therapeutic intervention in relapsing autoimmune demyelinating disease through induction of myelin-specific regulatory CD8 T cell responses.

Ashley A Brate, Alexander W Boyden, Farah R Itani, Lecia L Pewe, John T Harty, Nitin J Karandikar

Open access · goldAbstract read
In one paragraph

Article in Journal of translational autoimmunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Myelin-reactive CD8Journal of neuroinflammation · 2025
    Article
  3. A Functionally Distinct CXCR3Journal of immunology (Baltimore, Md. : 1950) · 2021
    Article
  4. Autoimmunity in 2019.Clinical reviews in allergy & immunology · 2020
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ashley A BrateDepartment of Pathology, University of Iowa, Iowa City, IA, USA.
Alexander W BoydenDepartment of Pathology, University of Iowa, Iowa City, IA, USA.
Farah R ItaniDepartment of Pathology, University of Iowa, Iowa City, IA, USA.
Lecia L PeweDepartment of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA.
John T HartyDepartment of Pathology, University of Iowa, Iowa City, IA, USA.
Nitin J KarandikarDepartment of Pathology, University of Iowa, Iowa City, IA, USA.
University of Iowa · USVeterans Health Administration · US

Funding

Immune Dysregulation During Multiple Sclerosis RelapseR01AI121567 · NIAID · UNIVERSITY OF IOWA · PI KARANDIKAR, NITIN J · 2016 to 2020
$3.8M
CNS-SPECIFIC REGULATORY CD8+ T CELLS IN AUTOIMMUNE DEMYELINATIONR01AI092106 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI KARANDIKAR, NITIN J · 2011 to 2015
$1.7M
BLRD VA I01 BX003677NIAID NIH HHS R01 AI092106NIAID NIH HHS R01 AI121567
6 · The paper itself

Abstract

Multiple Sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS). We have shown that CNS-specific CD8 T cells (CNS-CD8) possess a disease suppressive function in MS and its animal model, experimental autoimmune encephalomyelitis (EAE). Previous studies have focused on the role of these cells predominantly in chronic models of disease, but the majority of MS patients present with a relapsing-remitting disease course. In this study, we evaluated the therapeutic role of CD8 T cells in the context of relapsing-remitting disease (RR-EAE), using SJL mice. We found that PLP

Indexed as

CD8 T cellsEAERegulatory T cellsTherapy

Identifiers

PMID32161909
PMCPMC7065686
OpenAlexW2969730348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.